Apellis Pharmaceuticals, Inc. (APLS)
Automate Your Wheel Strategy on APLS
With Tiblio's Option Bot, you can configure your own wheel strategy including APLS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol APLS
- Rev/Share 6.1843
- Book/Share 1.309
- PB 13.3004
- Debt/Equity 2.8594
- CurrentRatio 4.0797
- ROIC -0.2946
- MktCap 2188123620.0
- FreeCF/Share -0.067
- PFCF -260.1502
- PE -9.7646
- Debt/Assets 0.5816
- DivYield 0
- ROE -1.0006
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | APLS | BofA Securities | Buy | Neutral | -- | $23 | May 9, 2025 |
| Downgrade | APLS | Raymond James | Strong Buy | Outperform | -- | $52 | May 9, 2025 |
| Initiation | APLS | Cantor Fitzgerald | -- | Overweight | -- | $44 | April 29, 2025 |
| Downgrade | APLS | Goldman | Buy | Neutral | -- | $36 | Dec. 17, 2024 |
| Initiation | APLS | Scotiabank | -- | Sector Outperform | -- | -- | Oct. 16, 2024 |
| Initiation | APLS | William Blair | -- | Outperform | -- | -- | Oct. 16, 2024 |
News
Apellis Pharmaceuticals: Have Some Patience
Published: May 20, 2025 by: Seeking Alpha
Sentiment: Positive
Apellis Pharmaceuticals is a Buy due to the significant FCF potential of SYFOVRE® and EMPAVELI®, with SYFOVRE® projected to exceed $1bn in annual sales by 2028. SYFOVRE® has shown efficacy in slowing GA progression and saw a 122% YoY sales increase in 2024, despite initial rollout issues. EMPAVELI® offers moderate sales and is in trials for additional indications, promising incremental cash flows and contributing to EBITDA positivity by 2026.
Read More
Apellis' Q1 Earnings and Revenues Miss Estimates, Stock Down
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Negative
APLS stock falls as it reports weaker-than-expected first-quarter 2025 results, wherein both earnings and revenues miss estimates.
Read More
Apellis Pharmaceuticals, Inc. (APLS) Q1 2025 Earnings Call Transcript
Published: May 07, 2025 by: Seeking Alpha
Sentiment: Neutral
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS ) Q1 2025 Earnings Conference Call May 7, 2025 8:30 AM ET Company Participants Tracy Vineis – Vice President-Communications Cedric Francois – Co-Founder and Chief Executive Officer Tim Sullivan – Chief Financial Officer David Acheson – Executive Vice President-Commercial Caroline Baumal – Chief Medical Officer Conference Call Participants Jon Miller – Evercore Tazeen Ahmad – Bank of America Securities Anupam Rama – JPM Steve Seedhouse – Cantor Colleen Kusy – Baird Eliana Merle – UBS Annabel Samimy – Stifel Biren Amin – Piper Sandler Yigal Nochomovitz – Citigroup Douglas Tsao – H.C. Wainwright Lachlan Hanbury-Brown – …
Read More
Apellis Pharmaceuticals (APLS) Reports Q1 Earnings: What Key Metrics Have to Say
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Positive
The headline numbers for Apellis Pharmaceuticals (APLS) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read More
Apellis Pharmaceuticals, Inc. (APLS) Reports Q1 Loss, Lags Revenue Estimates
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Negative
Apellis Pharmaceuticals, Inc. (APLS) came out with a quarterly loss of $0.74 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.54 per share a year ago.
Read More
Apellis Announces Craig Wheeler to Join the Board of Directors
Published: April 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
WALTHAM, Mass., April 21, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that Craig Wheeler, founder and chief executive officer of Headwaters Biotech Advisors, will join the Apellis Board of Directors, effective immediately. Mr. Wheeler is a highly accomplished executive with more than 30 years of leadership experience across the biopharmaceutical industry.
Read More
FDA Reviews Kidney Disease Drug From Apellis Pharmaceuticals
Published: April 01, 2025 by: Benzinga
Sentiment: Positive
The U.S. Food and Drug Administration (FDA) on Tuesday accepted and granted Priority Review designation to Apellis Pharmaceuticals, Inc.'s APLS supplemental New Drug Application (sNDA) for Empaveli (pegcetacoplan) for C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN).
Read More
Apellis Pharmaceuticals: A Mixed Bag
Published: March 05, 2025 by: Seeking Alpha
Sentiment: Positive
Commerical stage Apellis Pharmaceuticals, Inc. recently reported Q4 results that beat expectations. The company posted impressive revenue growth and cost reduction in FY2024. It is a bit of a complicated tale around this mid-cap, but the company looks set to move to profitability with the funding it has on hand.
Read More
Apellis Lead Drug Pegcetacoplan Represents Differentiated Asset: JP Morgan Analyst
Published: March 05, 2025 by: Benzinga
Sentiment: Positive
Last week, Apellis Pharmaceuticals Inc APLS reported a fourth-quarter earnings loss of 29 cents per share, beating the consensus loss of 37 cents. Sales increased 45.2% to $212.5 million, beating the consensus of $198.35 million.
Read More
Apellis Q4 Loss Narrower Than Expected, Syfovre Sales Drive Revenues
Published: March 03, 2025 by: Zacks Investment Research
Sentiment: Positive
APLS reports better-than-expected fourth-quarter 2024 results, wherein both earnings and revenues beat estimates, driven by strong sales of Syfovre.
Read More
Apellis Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference
Published: February 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
WALTHAM, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 10:30 a.m. ET.
Read More
Apellis Pharmaceuticals, Inc. (APLS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Published: February 21, 2025 by: Zacks Investment Research
Sentiment: Negative
Apellis Pharmaceuticals (APLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Apellis and Sobi Announce EMA Validation of Indication Extension Application for Aspaveli® (pegcetacoplan) for C3G and Primary IC-MPGN
Published: February 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
WALTHAM, Mass. and STOCKHOLM, Sweden, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi® (STO:SOBI) today announced the European Medicines Agency (EMA) has validated an indication extension application for Aspaveli® (pegcetacoplan) for the treatment of C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN), which are rare, chronic kidney diseases with no approved treatments.
Read More
Apellis Pharmaceuticals to Host Conference Call on February 28, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results
Published: February 14, 2025 by: GlobeNewsWire
Sentiment: Neutral
WALTHAM, Mass., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its fourth quarter and full year 2024 financial results on Friday, February 28, 2025, at 8:30 a.m.
Read More
About Apellis Pharmaceuticals, Inc. (APLS)
- IPO Date 2017-11-09
- Website https://www.apellis.com
- Industry Biotechnology
- CEO Dr. Cedric Francois M.D., Ph.D.
- Employees 705